The Setup: Two Choices, One Budget
When I sat down in Q1 2024 to renew our wound care contract, I had two paths in front of me. One was sticking with Molnlycke—brand we'd used for three years, mostly Mepilex and Mepiform for our post-surgical and chronic wound patients. The other was switching to a bundled offer from a composite supplier that promised '85% of the performance at 60% of the cost.'
If you're a procurement manager reading this, you already know the tension. The 'cheaper' option looks good on a quarterly P&L. But what about six months later? Or two years? That's the gap I want to bridge here—by comparing not just sticker prices, but the real costs that stack up when you're managing wound care across multiple departments.
Here's the framework I used: I broke the comparison into three dimensions—clinical effectiveness vs. cost, total cost of ownership (TCO), and vendor relationship & small-order handling. I'll walk you through each one, because the answer isn't 'Molnlycke is better' or 'generic is cheaper.' It's: it depends on your context.
Dimension 1: Clinical Outcomes vs. Unit Price
Let's start with the obvious. The alternative supplier's offer was roughly 35% cheaper per dressing—about $2.80 for their foam dressing vs. $4.30 for a standard Mepilex Border. At 500 dressings per month, that's a $750 monthly difference. Real money.
But here's the thing I learned after tracking 18 months of healing data: dressing cost isn't the cost of healing. It's the cost of the dressing. Healing cost includes nurse time, frequency of changes, and complications.
In our 2023 audit, patients on Mepilex (with Safetac technology) averaged 4.2 dressing changes per week for pressure injuries. Patients on the generic foam dressing? 6.1 changes per week. Why? Because the generic dressing adhered more aggressively to the wound bed, causing micro-trauma on removal—which slowed healing and required more frequent redressing.
Nurse time at our facility runs about $45/hour (loaded cost). If a dressing change takes 8 minutes, here's the math:
- Mepilex: (4.2 changes × 8 min) / 60 × $45 = $25.20/week in nursing labor
- Generic: (6.1 changes × 8 min) / 60 × $45 = $36.60/week in nursing labor
That's an $11.40/week additional labor cost per patient—$592.80 per year—just from using a dressing that requires more changes. Now add the dressing cost differential:
- Mepilex: $4.30 × 4.2 changes = $18.06/week
- Generic: $2.80 × 6.1 changes = $17.08/week
Total weekly cost per patient? Mepilex: $43.26 vs. Generic: $53.68. The 'cheaper' dressing actually costs 24% more per patient week.
What I mean is that the unit price comparison alone is deceptive—it only works if everything else is equal. But wound care isn't like buying paper towels. The product's design directly affects the workflow. Safetac technology isn't just a marketing term—it's a design feature that reduces adherence to moist wound beds, which means less trauma, less frequent changes, and fewer complications.
Conclusion on this dimension: For chronic wounds, pressure injuries, and fragile skin (think elderly patients or neonates), Molnlycke's higher unit price is offset by lower total care costs. For simple, acute wounds in younger patients? The generic might be fine—the clinical advantage narrows.
Dimension 2: Total Cost of Ownership (TCO) and Hidden Fees
This is where my cost-controller brain lives. Over the past 6 years of tracking every invoice and change order across our supply chain, I've learned one thing: the price on the quote is not the price you pay.
Let me walk you through the hidden costs I uncovered when comparing these two options:
Molnlycke (Direct Contract)
- Unit price: $4.30 (Mepilex Border, based on our contract pricing)
- Shipping: Included in annual contract
- Minimum order: $200 for first order, $100 thereafter
- Return policy: 30-day return on unopened cases
- Clinical support: Included (wound care specialist visits quarterly)
Composite Supplier (Aggregated Offer)
- Unit price: $2.80
- Shipping: $45 per order (orders under $200)
- Minimum order: $250
- Return policy: 15% restocking fee
- Clinical support: None included ($150/hour for phone consultation)
Now run the numbers for a typical month. We order $2,150 of Mepilex ($4.30 × 500 units). Shipping: $0. Total: $2,150.
For the composite supplier, we order $1,400 in dressings ($2.80 × 500 units). But we have to order in increments of $250—so maybe we overshoot by $50, getting 520 units at $1,456. Shipping: $45. Total: $1,501. Looks better—$649 less per month.
But wait. Remember the clinical support line. In Q3 2024, when we had two complex wound patients with atypical healing patterns, we called the Molnlycke specialist. No charge. With the composite supplier, we'd have paid $150/hour for a consultant we didn't know. Not to mention the restocking fee on the 60 units we might over-order to hit the minimum.
The 'cheap' option's TCO includes hidden cost categories: shipping minimums, restocking fees, absence of included clinical support, and the risk of over-ordering to meet minimums. Over 12 months, I calculated those hidden costs at roughly $1,800–$2,400—burying the 35% unit price advantage.
Conclusion on this dimension: Molnlycke's direct model is simpler and more transparent for TCO. The composite supplier's model hides costs in shipping and restocking fees. For a large facility with predictable ordering patterns, the composite model might still work—but for smaller facilities or those with variable demand, the hidden costs eat the savings.
Dimension 3: Small-Order Friendliness and Vendor Relationship
This one hits close to home. When I was starting out at a 15-bed rural clinic, I had a $4,000 annual wound care budget. I'd place $200 orders. The vendors who took those orders seriously? They're the ones I still use today, now that I'm managing a $120,000 wound care budget. The ones who treated my small orders like an inconvenience? I remember every single one.
Molnlycke's minimums are relatively low—$200 for the first order. I've placed $125 orders for Mepiform for a single patient with a hypertrophic scar. They didn't bat an eye.
The composite supplier's $250 minimum and $45 shipping fee—which kicks in below $200—effectively prices out small orders. A $125 order becomes $125 + $45 = $170 for $125 worth of product. That's a 36% surcharge. For cash-strapped small clinics, that's painful.
People assume that being 'small' means you have less bargaining power. The reality is that some suppliers—like Molnlycke, in my experience—treat small orders as relationship investments. The composite supplier treated my test order like data entry.
Why does this matter? Because wound care isn't a one-off purchase. It's a recurring need. The vendor who helps you through your first small order is building a foundation. The one who charges you 36% extra for the privilege of buying from them? They're pricing themselves into irrelevance when you grow.
Conclusion on this dimension: For small facilities, startup clinics, or departments with limited wound care budgets, Molnlycke is clearly more accessible. Their low minimums and included shipping on orders over $200 make them the practical choice. The composite supplier's model favors high-volume, predictable orders.
So What Should You Do?
I'm not here to tell you Molnlycke is 'better' in some absolute sense. I'm telling you where each option works—and where it doesn't.
Go with Molnlycke if:
- You treat chronic wounds, pressure injuries, or fragile skin (the clinical advantage is real)
- You want predictable TCO without hidden fees
- You're a smaller facility or just starting out
- You value included clinical support for complex cases
Consider the composite supplier if:
- Your patient population is primarily acute, simple wounds
- Your ordering volume is large and predictable ($5,000+/month)
- You have in-house wound care expertise (no need for vendor clinical support)
- You're willing to manage the hidden cost risk
The truth is, most facilities fall into the first category—at least partially. And that's why, after running these numbers, I renewed our Molnlycke contract for 2024. The savings from the generic option were illusory when I accounted for clinical outcomes and TCO.
But I also kept a small slush fund for acute wounds. Because the best procurement strategy isn't 'pick one and stick with it.' It's knowing when each option fits.
